Confirmation of cellular and plasma biomarkers in patients with long-lasting BOS
| . | Onset of BOS . | FEV1 ≤ 55% . | Histological BO . | LFS 3 . | LSS 2+3 . | No cGVHD . |
|---|---|---|---|---|---|---|
| Number of patients | 46 | 23 | 23 | 9 | 11 | 41 |
| BAFF, ng/mL | 7.3* | 8.0* | 9.1* | 8.0* | 7.7* | 3.5 |
| CD19+ B cells × 106/L | 146* | 120* | 117* | 90* | 129 | 317 |
| CD19+ B cells, % | 10.2* | 8.5* | 8.7* | 8.9* | 8.5* | 19.7 |
| Ratio BAFF/CD19+ | 0.18* | 0.19* | 0.18* | 0.47* | 0.21* | 0.02 |
| CD19+CD21low, % | 25.5* | 27.8* | 26.5* | 22* | 25.6* | 6.6 |
| CD4+ T cells, % | 23.62* | 21.2* | 21.8* | 24.3* | 23.2* | 17.5 |
| IgG, mg/dL | 533* | 580* | 512* | 584 | 449* | 1172 |
| . | Onset of BOS . | FEV1 ≤ 55% . | Histological BO . | LFS 3 . | LSS 2+3 . | No cGVHD . |
|---|---|---|---|---|---|---|
| Number of patients | 46 | 23 | 23 | 9 | 11 | 41 |
| BAFF, ng/mL | 7.3* | 8.0* | 9.1* | 8.0* | 7.7* | 3.5 |
| CD19+ B cells × 106/L | 146* | 120* | 117* | 90* | 129 | 317 |
| CD19+ B cells, % | 10.2* | 8.5* | 8.7* | 8.9* | 8.5* | 19.7 |
| Ratio BAFF/CD19+ | 0.18* | 0.19* | 0.18* | 0.47* | 0.21* | 0.02 |
| CD19+CD21low, % | 25.5* | 27.8* | 26.5* | 22* | 25.6* | 6.6 |
| CD4+ T cells, % | 23.62* | 21.2* | 21.8* | 24.3* | 23.2* | 17.5 |
| IgG, mg/dL | 533* | 580* | 512* | 584 | 449* | 1172 |
Indicates significant difference compared with patients without cGVHD.